Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results

Author： Lorenzetti Roberto   Prantera Cosimo  

Publisher： Future Science

ISSN： 2041-6792

Source： Clinical Investigation, Vol.3, Iss.12, 2013-12, pp. : 1187-1193

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Physicians’ perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 6, 2018-03 ,pp. : 773-783

John Wiley & Sons Inc

Access to resources Recommend Favorite

Appearance of hepatobiliary diseases in a population‐based cohort with inflammatory bowel diseases (Inflammatory Bowel Disease Cohort of the Uppsala Region)

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 8, 2015-08 ,pp. : 1288-1292

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: diverticulosis in inflammatory bowel diseases

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 39, Iss. 8, 2014-04 ,pp. : 899-900

John Wiley & Sons Inc

Access to resources Recommend Favorite

Manipulation of Intestinal Microbial Flora for Therapeutic Benefit in Inflammatory Bowel Diseases: Review of Clinical Trials of Probiotics, Prebiotics and Synbiotics

By  

Reviews on Recent Clinical Trials, Vol. 3, Iss. 3, 2008-09 ,pp. : 167-184

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases

By  

NEUROGASTROENTEROLOGY & MOTILITY (ELECTRONIC), Vol. 27, Iss. 8, 2015-08 ,pp. : 1057-1068

John Wiley & Sons Inc

Access to resources Recommend Favorite